Growth Metrics

Myriad Genetics (MYGN) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$0.29.

  • Myriad Genetics' EPS (Weighted Average and Diluted) fell 2083.33% to -$0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.33, marking a year-over-year decrease of 23828.12%. This contributed to the annual value of -$1.41 for FY2024, which is 5581.52% up from last year.
  • Latest data reveals that Myriad Genetics reported EPS (Weighted Average and Diluted) of -$0.29 as of Q3 2025, which was down 2083.33% from -$3.57 recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' EPS (Weighted Average and Diluted) registered a high of $0.3 during Q3 2021, and its lowest value of -$3.57 during Q2 2025.
  • Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.34 (2023), whereas its average is -$0.54.
  • As far as peak fluctuations go, Myriad Genetics' EPS (Weighted Average and Diluted) surged by 25000.0% in 2021, and later plummeted by 77073.17% in 2025.
  • Myriad Genetics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.1 in 2021, then tumbled by 420.0% to -$0.52 in 2022, then soared by 34.62% to -$0.34 in 2023, then tumbled by 37.97% to -$0.47 in 2024, then soared by 38.18% to -$0.29 in 2025.
  • Its last three reported values are -$0.29 in Q3 2025, -$3.57 for Q2 2025, and -$0.0 during Q1 2025.